Bank of America acquires Cerus stake: what it means for Cerus stock
Published on 10/06/2026 at 02:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cerus Corporation (US1570851014) drew a fresh ownership signal after Bank of America acquired 868,457 shares during the second quarter, equal to 0.43 percent of the company. MarketBeat reported the transaction on October 1, 2026, while Cerus continues to build its blood-safety platform around the INTERCEPT system.
Bank of America adds 868,457 shares
The filing gives the ownership move a concrete scale: the shares were valued at USD 2.5 million when disclosed, and Bank of America held approximately 0.43 percent of Cerus after the purchase. Institutional investors and hedge funds collectively owned 78.37 percent of the company in the same disclosure.
The ownership data arrives against a business update centered on product expansion rather than a change in Cerus' core mission. The company develops pathogen-reduction technologies for platelets, plasma, cryoprecipitation and red blood cells, with the INTERCEPT Blood System as its principal platform.
Guidance points to double-digit growth
In the second quarter of 2026, worldwide product revenue increased 10.00 percent year over year to USD 57.40 million, according to the Yahoo Finance transcript dated July 30, 2026. First-half product revenue reached USD 111.10 million, up 16.00 percent from USD 95.70 million in the first half of 2025.
Management also raised the low end of its full-year 2026 product revenue guidance to USD 229 million-USD 231 million from USD 227 million-USD 231 million. Full-year IFC revenue guidance increased to USD 23 million-USD 25 million from USD 22 million-USD 24 million. The company reported a GAAP net loss of USD 2.90 million for the second quarter, compared with USD 5.70 million in the second quarter of 2025, while adjusted EBITDA was USD 3.00 million.
Market value and listing
Cerus had a market capitalization of USD 479.6 million on October 1, 2026, and its 52-week range was USD 1.38 to USD 3.47 on Nasdaq. The range frames the ownership filing against a company still reporting losses but expanding revenue and maintaining positive adjusted EBITDA for the ninth consecutive quarter.
Cerus' investor materials describe the INTERCEPT Blood System for platelets and plasma as globally available, with U.S. approval for INTERCEPT Fibrinogen Complex and the red blood cell system in late-stage clinical development. The platform's commercial progress and the pace of regulatory execution remain the central operating variables for the equity story.
Cerus Corporation at a glance
- Company: Cerus Corporation
- ISIN: US1570851014
- Ticker: CERS
- Primary exchange: Nasdaq
- Market capitalization: USD 479.6 million (as of October 1, 2026)
- 52-week range: USD 1.38-USD 3.47 (as of October 1, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
